


PHARMACEUTICAL 2021



ROCKET PHARMACEUTICALS INC. Rank 118 of 409





PHARMACEUTICAL 2021



ROCKET PHARMACEUTICALS INC. Rank 118 of 409

The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 128% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is -4.0%, being 351% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	487,345
Cost of Goods Sold	0
Intangible Assets	30,815
Liabilities, Current	32,617
Liabilities, Non-Current	634
Other Assets	53,458
Other Compr. Net Income	-62
Other Expenses	6,967
Other Liabilities	54,054
Other Net Income	-580
Property and Equipment	19,206
Research and Development	106,382
Revenues	2,150
Selling, General and Administrative Expense	27,921

Output Variable	Value in 1000 USD
Assets	590,824
Liabilities	87,305
Expenses	141,270
Stockholders Equity	503,519
Net Income	-139,700
Comprehensive Net Income	-139,731
Economic Capital Ratio	-4.0%